Several LPAR1 antagonists have recently been included in clinical trials for the treatment of idiopathic pulmonary fibrosis and diffuse cutaneous systemic sclerosis [39, 40]. This evidence concerns the gene LPAR1 and idiopathic pulmonary fibrosis.